A - Agilent Technologies, Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
69.80
-0.15 (-0.21%)
As of 3:04PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close69.95
Open70.31
Bid69.99 x 800
Ask70.00 x 900
Day's Range69.79 - 70.54
52 Week Range61.01 - 82.27
Volume1,527,681
Avg. Volume2,751,745
Market Cap22.056B
Beta (3Y Monthly)1.35
PE Ratio (TTM)20.27
EPS (TTM)3.44
Earnings DateAug 12, 2019 - Aug 16, 2019
Forward Dividend & Yield0.66 (0.94%)
Ex-Dividend Date2019-07-01
1y Target Est82.64
Trade prices are not sourced from all markets
  • Agilent to Acquire BioTek, Cell Analysis Portfolio to Expand
    Zacks5 days ago

    Agilent to Acquire BioTek, Cell Analysis Portfolio to Expand

    Agilent Technologies (A) enters into an agreement to buy BioTek Instruments, which is likely to strengthen its cell analysis capabilities and expand presence in life science research space.

  • Agilent Technologies, Inc. (NYSE:A): Earnings Expected To Remain Subdued
    Simply Wall St.5 days ago

    Agilent Technologies, Inc. (NYSE:A): Earnings Expected To Remain Subdued

    Since Agilent Technologies, Inc. (NYSE:A) released its earnings in April 2019, analyst consensus outlook seem bearish...

  • Moody's6 days ago

    Agilent Technologies, Inc. -- Moody's: Agilent Technologies' acquisition of BioTek increases leverage, but adds complementary growth driver

    Moody's Investors Service commented that Agilent Technologies Inc.'s announcement that it has agreed to acquire BioTek Instruments for $1.17 billion is strategically sound, adding to Agilent's rapidly growing cell analysis franchise. There is no change to Agilent's Baa2 senior unsecured rating or stable outlook, given Agilent's strong overall financial profile and Moody's expectations for deleveraging over the next 12 to 18 months. For additional information, please refer to Moody's issuer comment on Agilent Technologies Inc. available on www.moodys.com.

  • Benzinga6 days ago

    Blue Lion To Sell Back All Its HomeStreet Shares

    Blue Lion Group will sell all of its shares of HomeStreet, Inc. (NASDAQ: HMST ) common stock to the company. The group owns approximately 6.48% of the HomeStreet’s common stock. Under the share purchase ...

  • Benzinga6 days ago

    Agilent Will Acquire BioTek Instruments In $1.16B Deal

    Agilent (NYSE: A ) will acquire BioTek Instruments in a $1.165 billion deal. The transaction is expected to be completed in Agilent’s fiscal fourth quarter. BioTek designs, manufactures and distributes ...

  • MarketWatch6 days ago

    Agilent to acquire privately held BioTek instruments for $1.165 billion

    Life sciences company Agilent Technologies Inc. said Thursday it has agreed to acquire privately held BioTek Instruments for $1.165 billion. Including expected tax benefits, the company expects to pay about $1.05 billion, Agilent said in a statement. BioTek specializes in plate readers and imaging systems and generated revenue of $162 million fiscal 2018 to end December. Revenue is expected to grow about 10% in 2019. The deal is expected to close in Agilent's fiscal fourth quarter and to add 2 cents to 4 cents to fiscal 2020 non-GAAP per-share earnings. Agilent shares rose 0.6% premarket and have gained about 9% in 2019, while the S&P 500 has gained 19%.

  • Agilent to Acquire BioTek, Strengthening Leadership Position in Growing Cell Analysis Segment
    Business Wire6 days ago

    Agilent to Acquire BioTek, Strengthening Leadership Position in Growing Cell Analysis Segment

    Agilent Technologies Inc. (NYSE:A) today announced it has signed a definitive agreement to acquire privately-owned BioTek Instruments for $1.165 billion. With anticipated tax benefits for Agilent, the net purchase price is expected to be approximately $1.05 billion. BioTek is a global leader in the design, manufacture and distribution of innovative life science instrumentation.

  • Facebook churns out a per-employee profit of $635K per year. How that compares with Apple, Google, Cisco, Oracle, Salesforce and others
    American City Business Journals9 days ago

    Facebook churns out a per-employee profit of $635K per year. How that compares with Apple, Google, Cisco, Oracle, Salesforce and others

    Facebook makes more profit per employee than any other tech company on the Fortune 500: A whopping $634,694 per year. Here's how that compares with other major tech employers like Google, Apple and Cisco.

  • Bloomberg13 days ago

    Even Trade War Winners Can Lose. Just Ask Vietnam

    (Bloomberg Opinion) -- In war, even the winners pay a price.Vietnam's portrayal as a clear beneficiary of the U.S.-China trade conflict was overdue for a reality check. President Donald Trump provided one, trash talking the country with the kind of language he once reserved for China and Mexico. Vietnam is “almost the single worst abuser of everybody,” he declared to Fox Business Network last week. That's a turnabout from earlier in the year when Trump praised Vietnam and said it was a model North Korea would be well advised to follow.The Communist state has an industrial policy, cheap factory wages and a burgeoning trade surplus that resemble the China of years past, as I wrote here in May. In Vietnam's favor, it’s small relative to China and has had amicable relations with America in recent years. Still, playing the trade-conflict game has costs as well as benefits.Positioning yourself as a key part of the export chain leaves you vulnerable when global demand weakens. A rush to expand manufacturing can create internal tensions, such as the clustering of factories in relatively small areas, large-scale domestic migration and strains on infrastructure. And pay doesn’t tend to stay low forever.If Trump's disparaging remarks got lost amid the bonhomie between him and Chinese leader Xi Jinping, the Department of Commerce grabbed Vietnam's attention Tuesday. A preliminary ruling imposes an excise of more than 400% on steel imports from the country. The contention is that businesses in South Korea and Taiwan are avoiding higher duties by routing steel through Vietnam, where it undergoes some cosmetic nips and tucks before being shipped to the U.S.Commerce has hit on Vietnam’s key vulnerability. A lot of stuff is flowing from China to Vietnam as firms increase purchases and ramp up production there to avoid tariffs. In part, Chinese-made goods arrive for final assembly before heading to ultimate destinations in America.That's the supply chain world. Everything is linked. It's possible Trump's definition of “made in China” could evolve, and then Vietnam will really find itself under the spotlight.Vietnam boosters should be careful what they wish for. Much of the increase in the country’s trade surplus with the U.S. in the past year has been associated with goods subject to tariffs – if they come from China. Vietnam's share of U.S. imports is up, relative to China, in many categories. The big ones are phones and parts, textile fibers, furniture, wood products and footwear.Vietnam's turn in the sun has coincided with a slackening of global growth that's wounded manufacturing. The country's total exports probably grew around 6.5% in the first four months of 2019. That’s not bad, but is well down from the 13.2% clocked last year, according to a World Bank report released this week. Phones, the largest single export and about 20% of the total, declined. Footwear, garments and computers gained, but less rapidly as a result of waning global demand. The lesson is you can bulk up as an export powerhouse all you want, but the power has to be present for the idea to work.Then there are the internal strains. As the World Bank notes, the export machine is concentrated in about 10 of Vietnam's 63 provinces, such as the economic centers around Hanoi and Ho Chi Minh City. The lopsided geography of development creates bottlenecks and other logistics challenges, not least the need to manage a surge in internal migration.This all sounds like China, doesn't it? Malaysia certainly looks at Vietnam and sees something that looks like the rising manufacturing giant of the late 1980s and early 1990s. This came up, unprompted, in a couple of meetings with current and former officials in Kuala Lumpur and Penang last month.On Penang Island just off the northwest coast of the Malaysian peninsula, the government set up an industrial zone in the early 1970s and attracted manufacturers such as Intel Corp. and Dell. They’re still there, along with a who’s who of electronics and technology including Agilent Technologies Inc.Malaysia has been trumpeting its own prowess in attracting foreign direct investment this year, even going so far as to declare itself a winner. If anyone understands the threat from Vietnam, it’s Southeast Asian neighbors such as Malaysia .In the arena of trade victors and vanquished, it’s a good idea to look over your shoulder. To contact the author of this story: Daniel Moss at dmoss@bloomberg.netTo contact the editor responsible for this story: Matthew Brooker at mbrooker1@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Daniel Moss is a Bloomberg Opinion columnist covering Asian economies. Previously he was executive editor of Bloomberg News for global economics, and has led teams in Asia, Europe and North America.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.

  • 5 Top & Flop ETF Areas of Q2
    Zacks14 days ago

    5 Top & Flop ETF Areas of Q2

    Dovish Fed comments and chances of U.S.-China trade truce kept the market steady in the second quarter. These ETF areas won and lost in the second quarter.

  • Moody's16 days ago

    Agilent Technologies, Inc. -- Moody's announces completion of a periodic review of ratings of Agilent Technologies, Inc.

    Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Agilent Technologies, Inc. New York, July 01, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Agilent Technologies, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.

  • Arts, cultural groups talk about reaching broader audiences
    American City Business Journals22 days ago

    Arts, cultural groups talk about reaching broader audiences

    Leaders of Art Museum, Wichita Festivals, Asian Association and Hispanic Chamber participated in panel discussion.

  • Business Wire23 days ago

    Agilent Introduces Breakthrough Flow Cytometer

    Agilent Technologies Inc. (NYSE:A) today introduced its first new product from recently acquired ACEA Biosciences, at the 34th Congress of the International Society for Advancement of Cytometry, CYTO 2019 Congress, being held June 22–26, 2019 in Vancouver, Canada. The Agilent NovoCyte Advanteon Flow Cytometer is now one of the most sensitive cell analyzers available on the market. Flow cytometers are integral to basic research, drug discovery, and clinical diagnostics.

  • Business Wire29 days ago

    New State of the Art Facility Increases Agilent’s Capacity to Produce Nucleic Acid-Based Therapeutics

    Agilent Technologies Inc. (NYSE:A) today announced the opening of a production facility in Colorado that more than doubles its capacity to develop and manufacture “oligos,” which are short DNA and RNA molecules that customers use to produce nucleic acid-based therapeutics. Agilent expects the demand for therapeutic oligo manufacturing to grow near 10% each year through 2025, to over $750 million by 2025. This facility will enable Agilent to meet this growing demand and to continue being a partner of choice to pharmaceutical and biotech companies.

  • Agilent Announces Receipt of FDA Approval for pharmDX Assay
    Zackslast month

    Agilent Announces Receipt of FDA Approval for pharmDX Assay

    Agilent (A) receives approval on the expanded use of its PD-L1 IHC 22C3 pharmDx assay.

  • Why Is Agilent (A) Up 3.9% Since Last Earnings Report?
    Zackslast month

    Why Is Agilent (A) Up 3.9% Since Last Earnings Report?

    Agilent (A) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Is Agilent Technologies, Inc.'s (NYSE:A) CEO Salary Justified?
    Simply Wall St.last month

    Is Agilent Technologies, Inc.'s (NYSE:A) CEO Salary Justified?

    Mike McMullen has been the CEO of Agilent Technologies, Inc. (NYSE:A) since 2015. This report will, first, examine the...

  • 9 major Bay Area tech employers pay a typical worker more than $200K per year
    American City Business Journalslast month

    9 major Bay Area tech employers pay a typical worker more than $200K per year

    Large Bay Area tech employers that pay a typical employee more than $200,000 per year include the typical suspects like Google parent Alphabet Inc., Facebook and Netflix. But several companies that are lesser-known outside Silicon Valley also pay top dollar for talent.

  • Hedge Funds Are Buying Agilent Technologies Inc. (A)
    Insider Monkeylast month

    Hedge Funds Are Buying Agilent Technologies Inc. (A)

    Legendary investors such as Jeffrey Talpins and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don't publish. Small cap stocks -especially when they are screened well- can generate substantial outperformance versus a boring index fund. That's why we analyze the […]

  • Business Wirelast month

    Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma (HNSCC)

    PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA®

  • Morningstarlast month

    An Up-and-Comer From a Topnotch Fund Group

    Artisan Partners Asset Management APAM has long earned Morningstar's admiration. As a result, Artisan has earned a Positive Parent rating, one of the pillars that support Morningstar Medalist designations for a number of Artisan funds. Of the 15 open-end strategies Artisan offers, 12 are on Morningstar's coverage list, and all of those have earned Morningstar Analyst Ratings of Bronze, Silver, or Gold.

  • Business Wirelast month

    Agilent Technologies Announces Webcasts for Investment Community

    Agilent Technologies Inc. today announced the following upcoming webcasts for the investment community:

  • Business Wirelast month

    Agilent Survey of Pharma Lab Leaders Uncovers Challenges in Workflow and Laboratory Efficiencies

    Agilent Technologies Inc. (NYSE:A) announced today the results of its first Pharma Lab Leaders Survey looking to gather insights from pharmaceutical, biopharmaceutical, and contract research laboratories in seven countries around the world. Respondents included 650 laboratory managers, directors, and supervisors from China, Germany, India, South Korea, Switzerland, Austria, and the United States. “We were extremely pleased that Agilent wanted to work with us again to explore the challenges and opportunities within this unique group of laboratories,” said Paljit Sohal, principal consultant, of Frost & Sullivan.

  • Business Wirelast month

    Agilent Introduces Intelligent LC/MS System for Chromatographers at ASMS 2019

    Agilent Technologies Inc. (NYSE:A) introduced the newest member of its LC/MS portfolio today at the American Society for Mass Spectrometry Conference (ASMS) which is being held June 2 through June 6 in Atlanta, Georgia. The new Agilent InfinityLab LC/MSD iQ System incorporates ‘designed-in’ smart features, software, and hardware developed specifically for chemists and chromatographers who will benefit from the intuitive design and greater level of detail generated by a mass selective detector. An early maintenance feedback feature allows lab managers to plan routine maintenance on the lab’s schedule resulting in a focus on overall productivity.